| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 300.19 | 7.4% |
| Total Income | 300.19 | 7.4% |
| Expenditure | 259.46 | 9.4% |
| PBT | 63.14 | 59.0% |
| Net Profit | 15.40 | 85.3% |
| OPM | 13.57% | 1.63pp |
| NPM | 5.13% | 2.16pp |
| EPS | 0.07 | 75.0% |
Green Thumb Industries Reports Q1 2026 Revenue Up 7.4% to $300.2 Million
07 May 2026 · 7 May, 1:40 am
Summary
Green Thumb Industries reported a strong start to 2026, with first quarter revenue reaching $300.2 million, a 7.4% increase year-over-year. Normalized EBITDA was $93.5 million, representing 31.2% of revenue. The company generated $76.0 million in cash flow from operations. Subsequent to quarter end, Green Thumb was conditionally awarded a Texas Compassionate Use Program license and repurchased additional shares.
Key Highlights
- 1
Green Thumb Industries reported first quarter revenue of $300.2 million, an increase of 7.4% over the same period in the prior year.
- 2
The company's GAAP net income was $15.4 million, equating to $0.07 per basic and diluted share for Q1 2026.
- 3
Normalized EBITDA for the first quarter was $93.5 million, representing 31.2% of revenue.
- 4
Green Thumb Industries generated $76.0 million in cash flow from operations during the first quarter.
- 5
The company repurchased approximately 6.0 million of its Subordinate Voting Shares for $33.3 million during the quarter.
- 6
Subsequent to quarter end, Green Thumb Industries was conditionally awarded a Texas Compassionate Use Program license for vertically integrated operations.
- 7
The company increased its syndicated credit facility by $50.0 million.
Management Comments
Ben Kovler
“The Green Thumb team delivered a strong start to 2026, with first quarter revenue of $300 million, Normalized EBITDA of $94 million and cash flow from operations of $76 million. The recent federal action to reschedule medical cannabis from Schedule I to Schedule III is a historic step forward for our business, for investors, and for the country. Our conviction in Green Thumb remains as strong as ever, as reflected in the approximately 13.4 million shares we have repurchased so far this year. As the landscape around us continues to evolve, our team remains focused on disciplined execution and building for the future.”
Anthony Georgiadis
“With medical cannabis now rescheduled, the resulting Section 280E relief for the medical portion of our business creates meaningful flexibility to reinvest in our operations, our people, and the communities we serve. Consumer demand for THC continues to rise, and rescheduling helps create a more practical framework for companies like Green Thumb to meet that demand responsibly while continuing to grow and scale our business. Our team is ready for this next chapter in cannabis, and we look forward to continuing to serve patients and consumers while keeping momentum at the federal level toward broader reform and legalization.”
Informational and educational content only. Not investment advice.